Biology:Mitogen-activated protein kinase kinase

From HandWiki
Revision as of 14:42, 10 February 2024 by Steve Marsio (talk | contribs) (change)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Kinase enzyme
Mitogen-activated protein kinase kinase
Identifiers
EC number2.7.12.2
Databases
IntEnzIntEnz view
BRENDABRENDA entry
ExPASyNiceZyme view
KEGGKEGG entry
MetaCycmetabolic pathway
PRIAMprofile
PDB structuresRCSB PDB PDBe PDBsum

Mitogen-activated protein kinase kinase (also known as MAP2K, MEK, MAPKK) is a dual-specificity kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK).

MAP2K is classified as EC 2.7.12.2.

There are seven genes:

The activators of p38 (MKK3 and MKK6), JNK (MKK4 and MKK7), and ERK (MEK1 and MEK2) define independent MAP kinase signal transduction pathways.[1] The acronym MEK derives from MAPK/ERK Kinase.[2]

Role in melanoma

MEK is a member of the MAPK signaling cascade that is activated in melanoma.[3] When MEK is inhibited, cell proliferation is blocked and apoptosis (controlled cell death) is induced.

See also

References

  1. "Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms". Science 267 (5198): 682–5. 1995. doi:10.1126/science.7839144. PMID 7839144. Bibcode1995Sci...267..682D. 
  2. Dwivedi, Gaurav; Kemp, Melissa L. (February 15, 2012). "Systemic Redox Regulation of Cellular Information Processing". Antioxidants & Redox Signaling 16 (4): 374–80. doi:10.1089/ars.2011.4034. PMID 21939387. 
  3. Falchook, Gerald S. et al. (2012). "Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial". The Lancet Oncology 13 (8): 782–789. doi:10.1016/S1470-2045(12)70269-3. PMID 22805292. 

External links